Caristo Diagnostics secures £13m Series A financing led by Oxford Science Enterprises to expand cardiac care technology.
The financing round was led by Oxford Science Enterprises and will support market expansion in the UK, EU, and United States.
Caristo Diagnostics is a medical technology company developing advanced diagnostic tools for cardiac and vascular diseases. It provides AI-assisted imaging platforms designed to predict and prevent heart attacks.
Caristo Diagnostics has raised £13m in the final tranche of its Series A funding round to accelerate the commercial rollout of its cardiovascular diagnostic tools. The investment was led by Oxford Science Enterprises, with participation from BGF, Longwall Venture Partners, Oxford Investment Consultants, and the University of Oxford. The company will use the capital to advance its AI-powered CaRi-Heart technology into major global markets and establish a foothold in the United States. This financing brings the firm total venture capital backing to over £23m.
From the founder
"We are thrilled that five successful institutional investors participated in the financing round which validates the vast clinical and business potential of Caristo’s innovations"
Oran Muduroglu
Board Chairman at Caristo Diagnostics
Investor perspective
"We invest in companies with the potential to revolutionise healthcare and become global category leaders and that is why we are proud to back the incredible team at Caristo,"
Heather Roxborough
senior partner of Health Tech, Oxford Science Enterprises
Use of funds
- 01Expand into international markets
- 02Continue product development
Investors
Heather Roxborough
Oxford Science Enterprises
BGF
Longwall Venture Partners
Oxford Investment Consultants
Oxford University
Categories
About the company
Caristo Diagnostics
Caristo Diagnostics develops AI-assisted tools for cardiac and vascular disease diagnostics.